Apollomics

Apollomics is committed to the development of cancer immunotherapy and targeted drug programs. To date, it has conducted research related to non-small cell lung cancer, malignant glioma, solid tumors, and relapsed or refractory acute myeloid leukemia, all of which have entered the clinical stage.APL-101, a drug developed by Apollomics, is a novel oral and highly selective small molecule c-Met inhibitor that targets various tumor c-Met dysregulation pathways. APL-101 has demonstrated tumor suppression effects in gastric cancer, liver cancer, pancreatic cancer, and lung cancer. It is currently undergoing Phase II clinical trials in 15 countries and regions and has initiated combination therapies with Keytruda, Osimertinib, and other leading cancer drugs.On January 7, 2019, the company announced its name change from CBT Pharmaceuticals, Inc. to Apollomics, Inc.